Showing results (841-850 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 26, 2012
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell lineRoudy Chiminch Ekyalongo, Toru Mukohara, Yu Kataoka, et al.
Investigational New Drugs|July 26, 2012
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancerGary Hudes, Scott T Tagawa, Young E Whang, et al.
Investigational New Drugs|August 14, 2012
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumorsDon G Morris, Xiaolan Feng, Lisa M DiFrancesco, et al.
Investigational New Drugs|September 15, 2012
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS productionDurvanei Augusto Maria, Jean Gabriel de Souza, Katia L P Morais, et al.
Investigational New Drugs|July 10, 2012
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implicationsAntonio Garcia-Gomez, Enrique M Ocio, Atanasio Pandiella, et al.
Investigational New Drugs|July 7, 2012
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokineticsNwabundo Nwankwo, Zhe Zhang, Ting Wang, et al.
Investigational New Drugs|July 4, 2012
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerChristian Manegold, Johan Vansteenkiste, Felipe Cardenal, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Investigational New Drugs|June 15, 2012
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxelYong Sang Hong, Kyu-pyo Kim, Hyeong-Seok Lim, et al.
Investigational New Drugs|June 21, 2012
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical studyAnne Sudaka, Antoine Susini, Cristiana Lo Nigro, et al.
Pageof 372